NFE2L2 and COVID-19: Together, our data show that proxalutamide up-regulates NRF2 protein levels and decreases inflammation in the lungs induced by poly(I:C), suggesting a possible benefit of proxalutamide against SARS-CoV-2-associated inflammatory responses and mortality in COVID-19 patients.